NCT06508762View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

September 10, 2024

Study Completion Date

September 10, 2024

Conditions

Pain

Interventions

DRUG

VX-993

Tablet and Suspension for Oral Administration.

Trial Locations (1)

84124

ICON Salt Lake City, Salt Lake City

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06508762 - A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 | Biotech Hunter | Biotech Hunter